Results 41 to 50 of about 48,845 (222)

Effect of isavuconazole on the pharmacokinetics of sunitinib and its mechanism

open access: yesBMC Cancer
Background Sunitinib, a newly developed multi-targeted tyrosine kinase inhibitor (TKI), has become a common therapeutic option for managing advanced renal cell carcinoma (RCC).
Jinyu Hu   +7 more
doaj   +1 more source

Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma

open access: yesScientific Reports, 2022
Sunitinib, a VEGF blockade, is used to treat clear cell renal cell carcinoma (ccRCC). However, the anti-cancer treatment effects of sunitinib do not last long in ccRCC patients.
Hyun Ji Hwang   +4 more
doaj   +1 more source

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer

open access: yes, 2013
Background We evaluated the maximum tolerated dose (MTD) and safety of sunitinib plus capecitabine/cisplatin (XP) or capecitabine/oxaliplatin (XELOX) in Korean patients with advanced gastric cancer (GC).
Lin, X.   +10 more
core   +1 more source

Patient‐Derived Glioblastoma Organoids for AI‐Guided Prediction of Therapeutic Response

open access: yesAdvanced Science, EarlyView.
Patient‐derived glioblastoma organoids provide clinically relevant models that preserve tumor heterogeneity and enable integrated AI‐driven analysis of imaging, molecular, and treatment‐response data. Their convergence with advanced analytics supports predictive, personalized therapeutic strategies and may accelerate translation from patient‐specific ...
Sandbhor Puja   +15 more
wiley   +1 more source

Sunitinib for metastatic renal cell carcinoma

open access: yes, 2010
Sunitinib is an orally available, multitargeted tyrosine kinase inhibitor licensed for the treatment of metastatic renal cell carcinoma. This article is an in-depth review of the mechanism of action of sunitinib, rationale for dose and schedule ...
Lisa Pickering   +2 more
core   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac   +16 more
wiley   +1 more source

Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats [PDF]

open access: yes
High-dose imatinib reverses cardiopulmonary remodeling but adverse effects limit its clinical use. Efficacy of the multi-kinase inhibitor sunitinib remains questionable.
ヤマノ, ヨシアキ   +21 more
core   +1 more source

Fixed drug eruption related to sunitinib: a case report [PDF]

open access: yes, 2018
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor. It has been approved for the treatment of gastro-intestinal stromal tumor and advanced renal cell carcinoma.
Bhatia, Anuradha   +6 more
core   +1 more source

Nasal Tuft Cell Markers Are Predictive of Overall Survival in Sinonasal Neuroendocrine and Sinonasal Undifferentiated Carcinomas

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated carcinoma (SNUC) are rare aggressive malignancies with no established prognostic markers. Because features of POU2F3+ small cell lung carcinomas have been identified in both tumors, we evaluated immunostaining for POU2F3, a tuft cell transcription factor, and ...
Nikolina Dioufa   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy